Botanical species · safety record

Rubia tinctorum

The EFSA Compendium of Botanicals holds 3 constituent measurements, 7 adverse-effect records and 3 genotoxicity assays for Rubia tinctorum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Rubia tinctorum L.

3Constituent measurements
10Safety records
7Cited sources
28Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 28 licensed products naming Rubia tinctorum as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

  • Root

What the records describe

Constituents measured

  • Anthraquinones2
  • Lucidin1

Plant parts

  • Roots and other underground parts10

Preparations

  • Drying (dehydration)5
  • Solvent extraction2

Effect types

  • Hepatotoxicity5
  • Nephrotoxicity2

Target tissues

  • Urogenital: kidneys4
  • Cardiovascular2
  • haematological2
  • Liver1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
AnthraquinonesRoots and other underground partsSolvent extractionResolve DOI
AnthraquinonesRoots and other underground partsHPLC-UVResolve DOI
LucidinRoots and other underground partsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
HepatotoxicityCardiovascular / haematologicalRoots and other underground partsDrying (dehydration)Rat (as animal)Chronic/long term toxicityResolve DOI
HepatotoxicityCardiovascular / haematologicalRoots and other underground partsDrying (dehydration)Rat (as animal)Chronic/long term toxicityResolve DOI
HepatotoxicityUrogenital: kidneysRoots and other underground partsDrying (dehydration)Rat (as animal)Chronic/long term toxicityResolve DOI
HepatotoxicityUrogenital: kidneysRoots and other underground partsDrying (dehydration)Rat (as animal)Chronic/long term toxicityResolve DOI
HepatotoxicityUrogenital: kidneysRoots and other underground partsDrying (dehydration)Rat (as animal)Chronic/long term toxicityResolve DOI
NephrotoxicityUrogenital: kidneysRoots and other underground partsRat (as animal)Short-term toxicityResolve DOI
NephrotoxicityLiverRoots and other underground partsRat (as animal)SubchronicResolve DOI

Genotoxicity testing

Outcomes of genotoxicity assays as recorded in the source. A negative assay is a result under those test conditions, not a clearance.

OutcomeEndpointTestTested organismMetabolic activationSource
Positivegene mutationbacterial gene mutation assaySalmonella typhimurium (as organism)No dataResolve DOI
Positivegene mutationbacterial gene mutation assayBacteria (as organism)With and withoutResolve DOI
PositiveDNA damage and/or repairotherRat (as animal)WithoutResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Jaeger, Ismene., Hafner, Christoph., Welsch, Claudia., Schneider, Klaus., Iznaguen, Hassan., Westendorf, Johannes. The mutagenic potential of madder root in dyeing processes in the textile industry . Mutation research-genetic toxicology and environmental mutagenesis, 2006, vol. 605, no. 1-2, p. 22-29. DOI
  2. WESTENDORF, J., POGINSKY, B., MARQUARDT, H., GROTH, G., MARQUARDT, H. THE GENOTOXICITY OF LUCIDIN, A NATURAL COMPONENT OF RUBIA-TINCTORUM L, AND LUCIDINETHYLETHER, A COMPONENT OF ETHANOLIC RUBIA EXTRACTS . Cell biology and toxicology, 1988, vol. 4, no. 2, p. 225-239. DOI
  3. Westendorf, J., Pfau, W., Schulte, A. Carcinogenicity and DNA adduct formation observed in ACI rats after long-term treatment with madder root, Rubia tinctorum L . Carcinogenesis, 1998, vol. 19, no. 12, p. 2163-2168. DOI
  4. Inoue, Kaoru., Yoshida, Midori., Takahashi, Miwa., Fujimoto, Hitoshi., Ohnishi, Kuniyoshi., Nakashima, Koichi., Shibutani, Makoto., Hirose, Masao., Nishikawa, Akiyoshi. Possible contribution of rubiadin, a metabolite of madder color, to renal carcinogenesis in rats . Food and chemical toxicology, 2009, vol. 47, no. 4, p. 752-759. DOI
  5. Inoue, Kaoru., Shibutani, Makoto., Masutomi, Naoya., Toyoda, Kazuhiro., Takagi, Hironori., Takahashi, Miwa., Fujimoto, Hitoshi., Hirose, Masao., Nishikawa, Akiyoshi. One-year chronic toxicity of madder color in F344 rats - Induction of preneoplastic/neoplastic lesions in the kidney and liver . Food and chemical toxicology, 2008, vol. 46, no. 10, p. 3303-3310. DOI
  6. Inoue, Kaoru., Shibutani, Makoto., Masutomi, Naoya., Toyoda, Kazuhiro., Takagi, Hironori., Uneyama, Chikako., Nishikawa, Akiyoshi., Hirose, Masao. A 13-week subchronic toxicity study of madder color in F344 rats. Food and chemical toxicology, 2008, vol. 46, no. 1, p. 241-252. DOI
  7. Ishii, Yuji., Inoue, Kaoru., Takasu, Shinji., Jin, Meilan., Matsushita, Kohei., Kuroda, Ken., Fukuhara, Kiyoshi., Nishikawa, Akiyoshi., Umemura, Takashi. Determination of Lucidin-Specific DNA Adducts by Liquid Chromatography with Tandem Mass Spectrometry in the Livers and Kidneys of Rats Given Lucidin-3-O-primeveroside . Chemical research in toxicology, 2012, vol. 25, no. 5, p. 1112-1118. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue